The Ultimate Guide to Exemestane to treat breast cancer in women

References

Goss, P. E., Ingle, J. N., Alés-Martínez, J. E., Cheung, A. M., Chlebowski, R. T., Wactawski-Wende, J., … & Winquist, E. (2011). Exemestane for breast-cancer prevention in postmenopausal women. New England Journal of Medicine364(25), 2381-2391.

Yardley, D. A., Noguchi, S., Pritchard, K. I., Burris, H. A., Baselga, J., Gnant, M., … & Melichar, B. (2013). Everolimus plus exemestane in postmenopausal patients with HR+ breast cancer: BOLERO-2 final progression-free survival analysis. Advances in therapy30(10), 870-884.

Pagani, O., Regan, M. M., Walley, B. A., Fleming, G. F., Colleoni, M., Láng, I., … & Ciruelos, E. (2014). Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. New England Journal of Medicine371(2), 107-118.